Details
Description
In this request we examined counts of individuals with gout using urate-lowering therapy (ULT) and captured switching between ULT drug products in the Sentinel Distributed Database (SDD). This analysis includes four reports:
- Report 1: We described counts of individuals with gout diagnoses and examines cardiovascular morbidities and gout severity among those individuals.
- Report 2: We described counts of incident users of the ULT products febuxostat and allopurinol and characterizes switching between doses and generic products.
- Report 3: We described counts of prevalent new users of the ULT products febuxostat and allopurinol and characterizes switching between doses and generic products.
- Report 4: We described counts of all users of the ULT products febuxostat and allopurinol and characterizes switching between doses and generic products.
The study period included data from January 1, 2009 to March 31, 2018. We distributed this request to 16 Data Partners on July 8, 2019.
Deliverables (4)
Sentinel Modular Program Report: Counts of Individuals with Gout Using Urate-Lowering Therapy (ULT) and Switching between ULT Products: A Descriptive Analysis, Report 1
Sentinel Modular Program Report: Counts of Individuals with Gout Using Urate-Lowering Therapy (ULT) and Switching between ULT Products: A Descriptive Analysis, Report 2
Sentinel Modular Program Report: Counts of Individuals with Gout Using Urate-Lowering Therapy (ULT) and Switching between ULT Products: A Descriptive Analysis, Report 3
Sentinel Modular Program Report: Counts of Individuals with Gout Using Urate-Lowering Therapy (ULT) and Switching between ULT Products: A Descriptive Analysis, Report 4